Xenetic Biosciences (United States)

company in Lexington, United States

XBIO Nasdaq ISIN US9840156023 SEC CIK 1534525 LEI 5493002WV0KYX8JXAH52
Follow Xenetic Biosciences (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $725.3K −29.4% vs same quarter last year
Net income −$1.7M −232.5% vs same quarter last year
EPS, diluted −$0.72 −118.2% vs same quarter last year
Operating cash flow −$662.1K −0.6% vs same quarter last year
Revenue by quarter
$648.8K
$593.3K
$589.9K
$1M
$766.3K
$806.9K
$660.6K
$725.3K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$60M−$40M−$20M$0$20MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$3M−$2.7M
FY24$2.5M−$4M
FY23$2.5M−$4.1M
FY22$1.7M−$6.6M
FY21$1.2M−$5.6M
FY20$436.9K−$10.9M
FY19$17.1K−$12.8M
FY18$0−$7.3M
FY17$7.6M−$3.6M
FY16$3M−$54.2M
FY15$0−$12.5M
FY14$0−$14.3M
FY13$1M−$8.6M
FY12$293.6K−$89.2K
FY11--
MarginsShare of revenue
  • Operating margin
  • Net margin
−80000%−60000%−40000%−20000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−95.2%−90.1%
FY24−168.2%−158.4%
FY23−177.8%−162.8%
FY22−393.6%−383.9%
FY21−495.1%−486.4%
FY20−3189.8%−2493.1%
FY19−75511.7%−74856.6%
FY18--
FY17−47.1%−47.4%
FY16−1581%−1806.9%
FY15--
FY14--
FY13−861.3%−857.9%
FY12−2160.8%−30.4%
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0$5MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19-
FY18−$6.5M
FY17$1.5M
FY16−$8.8M
FY15−$5.3M
FY14−$12.7M
FY13−$6.1M
FY12−$6.4M
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Xenetic Biosciences (United States)
  • Healthcare median
−80000%−60000%−40000%−20000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearXenetic Biosciences (United States)Healthcare median
FY25−90.1%−30.6%
FY24−158.4%−47%
FY23−162.8%−58%
FY22−383.9%−80.4%
FY21−486.4%−71.8%
FY20−2493.1%−62.2%
FY19−74856.6%−46.2%
FY18-−49.6%
FY17−47.4%−45.9%
FY16−1806.9%−36%
FY15-−37.8%
FY14-−35.5%
FY13−857.9%−37.1%
FY12−30.4%−29.1%
FY11-−27.9%